Aigen Investment Management LP Purchases Shares of 7,742 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

Aigen Investment Management LP bought a new stake in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 7,742 shares of the company's stock, valued at approximately $320,000.

Several other hedge funds and other institutional investors have also made changes to their positions in MIRM. Jones Financial Companies Lllp raised its position in Mirum Pharmaceuticals by 100.0% in the fourth quarter. Jones Financial Companies Lllp now owns 714 shares of the company's stock valued at $30,000 after purchasing an additional 357 shares during the period. R Squared Ltd purchased a new stake in shares of Mirum Pharmaceuticals during the 4th quarter valued at about $69,000. Avanza Fonder AB acquired a new position in Mirum Pharmaceuticals during the 4th quarter worth approximately $189,000. Y Intercept Hong Kong Ltd purchased a new position in Mirum Pharmaceuticals in the 3rd quarter worth approximately $215,000. Finally, Creative Planning purchased a new position in Mirum Pharmaceuticals in the 3rd quarter worth approximately $249,000.

Analysts Set New Price Targets

MIRM has been the topic of a number of analyst reports. HC Wainwright lifted their price objective on shares of Mirum Pharmaceuticals from $66.00 to $72.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Robert W. Baird boosted their price objective on shares of Mirum Pharmaceuticals from $50.00 to $55.00 and gave the stock an "outperform" rating in a report on Thursday, February 27th. Finally, Citigroup raised their target price on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the company a "buy" rating in a research note on Wednesday, November 13th. Ten research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Mirum Pharmaceuticals presently has a consensus rating of "Buy" and an average target price of $58.20.

Remove Ads

Mirum Pharmaceuticals Stock Up 2.1 %

NASDAQ MIRM traded up $0.91 on Wednesday, hitting $44.97. 656,157 shares of the stock traded hands, compared to its average volume of 525,640. The company has a current ratio of 3.34, a quick ratio of 3.15 and a debt-to-equity ratio of 1.33. The stock has a 50-day moving average of $47.31 and a 200 day moving average of $43.55. Mirum Pharmaceuticals, Inc. has a twelve month low of $23.14 and a twelve month high of $54.23. The company has a market capitalization of $2.20 billion, a P/E ratio of -22.26 and a beta of 1.04.

Mirum Pharmaceuticals (NASDAQ:MIRM - Get Free Report) last announced its quarterly earnings data on Wednesday, February 26th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.27) by ($0.22). The firm had revenue of $99.41 million for the quarter, compared to the consensus estimate of $96.64 million. Mirum Pharmaceuticals had a negative return on equity of 41.22% and a negative net margin of 31.69%. As a group, analysts expect that Mirum Pharmaceuticals, Inc. will post -1.43 earnings per share for the current fiscal year.

Insider Activity at Mirum Pharmaceuticals

In related news, CEO Christopher Peetz sold 9,102 shares of the business's stock in a transaction that occurred on Monday, February 3rd. The stock was sold at an average price of $48.22, for a total transaction of $438,898.44. Following the completion of the transaction, the chief executive officer now owns 115,920 shares in the company, valued at $5,589,662.40. The trade was a 7.28 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Jolanda Howe sold 750 shares of the company's stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total value of $32,115.00. Following the transaction, the senior vice president now owns 2,926 shares of the company's stock, valued at approximately $125,291.32. The trade was a 20.40 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 40,915 shares of company stock valued at $1,897,920 in the last quarter. Insiders own 22.87% of the company's stock.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.